-
-
-
-
-
-
-
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
-
-
-
-
-
-
-
Harmony Biosciences reports positive pitolisant bioequivalence study results
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025
-
-
-
-
-
-
-
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
-
-
-
-
-
-
-
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
-
-
-
-
-
-
-
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY
-
-
-
-
-
-
-
Harmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS Assets
-
1,199,232 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


